World Mental Health Day: Reds fan Paddy Pimblett opens up and urges people to speak out - Liverpool FC

7 days agoStewart WhittinghamandRebecca Brahde, North WestLFCPaddy the Baddy has opened up on mental health in Liverpool FC's campaignUFC fighter Paddy Pimblett has joined Liverpool FC's mental health campaign. In a video released by the club, Paddy "the Baddy" from Huyton, Liverpool, spoke of a close friend taking his own life and said it was "shocking" that it happens every 90 minutes in the UK. The 31-year-old has urged men to speak out on World Mental Health Day, as he said he had had his own mental health struggles. The lifelong Liverpool fan said: "I thought about suicide a couple of times" but added "I'm glad I'm here".'Club saved my life'The fighter said: "I was like, I'm meant to be the hardest one in the room... I can't go speak to anyone about this. "To man up, bottle it up and not say anything is just sewn into our being. "He added: "There are a lot of lads I know over the past 10 years who've taken their own lives and it's crazy when you think about it because Scousers are the most happy-go-lucky people in the world. "Every 90 minutes someone takes their own life, that's just absolutely shocking. "My whole family supports Liverpool.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.